TMEM41A expression based on
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison Statistical significance Normal-vs-Primary 3.621400E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer stage information is not available for 3 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Stage1
4.665200E-01
Normal-vs-Stage2
3.024000E-01
Normal-vs-Stage3
9.689200E-01
Normal-vs-Stage4
6.020500E-02
Stage1-vs-Stage2
1.166110E-02
Stage1-vs-Stage3
6.376800E-01
Stage1-vs-Stage4
2.598500E-02
Stage2-vs-Stage3
2.215200E-01
Stage2-vs-Stage4
5.044200E-01
Stage3-vs-Stage4
1.103360E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient race information is not available for 5 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Caucasian
3.965200E-01
Normal-vs-AfricanAmerican
2.976000E-01
Normal-vs-Asian
3.498000E-02
Caucasian-vs-AfricanAmerican
8.114000E-01
Caucasian-vs-Asian
1.932610E-01
AfricanAmerican-vs-Asian
6.905000E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient gender information is not available for 1 sample.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Male
3.108600E-01
Normal-vs-Female
4.336200E-01
Male-vs-Female
6.528600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient age information is not available for 1 sample.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Age(21-40Yrs)
7.683400E-01
Normal-vs-Age(41-60Yrs)
2.055800E-01
Normal-vs-Age(61-80Yrs)
4.587200E-01
Normal-vs-Age(81-100Yrs)
5.590200E-01
Age(21-40Yrs)-vs-Age(41-60Yrs)
2.662800E-01
Age(21-40Yrs)-vs-Age(61-80Yrs)
5.840200E-01
Age(21-40Yrs)-vs-Age(81-100Yrs)
7.327400E-01
Age(41-60Yrs)-vs-Age(61-80Yrs)
6.543600E-03
Age(41-60Yrs)-vs-Age(81-100Yrs)
8.924000E-02
Age(61-80Yrs)-vs-Age(81-100Yrs)
6.149000E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Drinking status is not available for 80 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Non Drinker
5.849800E-01
Normal-vs-Daily Drinker
5.463800E-01
Normal-vs-Weekly Drinker
1.638560E-01
Normal-vs-Occasional Drinker
1.112250E-01
Normal-vs-Social Drinker
4.332200E-01
Non Drinker-vs-Daily Drinker
7.599800E-01
Non Drinker-vs-Weekly Drinker
7.426600E-01
Non Drinker-vs-Occasional Drinker
8.574200E-02
Non Drinker-vs-Social Drinker
7.065600E-01
Daily Drinker-vs-Weekly Drinker
4.755200E-01
Daily Drinker-vs-Occasional Drinker
2.196200E-02
Daily Drinker-vs-Social Drinker
4.682000E-01
Weekly Drinker-vs-Occasional Drinker
7.708400E-02
Weekly Drinker-vs-Social Drinker
8.698200E-01
Occasional Drinker-vs-Social Drinker
2.258800E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma
Subtype descriptions Grade 1 Well differentiated (low grade)
Grade 2 Moderately differentiated (intermediate grade) Grade 3 Poorly differentiated (high grade)
Grade 4 Undifferentiated (high grade)
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Grade 1
1.656400E-01
Normal-vs-Grade 2
1.823690E-02
Normal-vs-Grade 3
4.976000E-02
Normal-vs-Grade 4
1.000000E+00
Grade 1-vs-Grade 2
1.93155999999028E-05
Grade 1-vs-Grade 3
1.86930000001251E-06
Grade 1-vs-Grade 4
1.656400E-01
Grade 2-vs-Grade 3
9.780000E-02
Grade 2-vs-Grade 4
1.823690E-02
Grade 3-vs-Grade 4
4.976000E-02
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Diabetes status information is not available for 30 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Diabetic
5.210600E-01
Normal-vs-NonDiabetic
3.384600E-01
Diabetic-vs-NonDiabetic
1.551640E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Pancreatitis status is not available for 39 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Pancreatitis
9.372300E-02
Normal-vs-NoPancreatitis
3.995600E-01
Pancreatitis-vs-NoPancreatitis
2.687600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Nodal metastais status is not available for 1 sample and cancer in nearby lymph nodes cannot be measured (NX) in 4 samples.
pathologic_N descriptions N0 No regional lymph node metastasis
N1 Metastases in 1 to 3 axillary lymph nodes N2 Metastases in 4 to 9 axillary lymph nodes
N3 Metastases in 10 or more axillary lymph nodes
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-N0
4.135400E-01
Normal-vs-N1
3.190000E-01
N0-vs-N1
3.645500E-02
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Whole exome sequencing data is not available for 3 samples.
TP53 mutation status is obtained from TCGA whole exome sequencing data. We downloaded Mutation Annotation Format (MAF) files (derived from VarScan2) from Genomic Data Commons portal. The sample with/without TP53 mutation were matched with RNA-seq data
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-TP53-Mutant
3.425700E-02
Normal-vs-TP53-NonMutant
5.312000E-01
TP53-Mutant-vs-TP53-NonMutant
2.1985999998364E-07
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
